- Home
- MNY vs LSB Comparison
MNY vs LSB Comparison
Compare MNY & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNY
- LSB
- Stock Information
- Founded
- MNY 2014
- LSB 2002
- Country
- MNY Singapore
- LSB China
- Employees
- MNY N/A
- LSB N/A
- Industry
- MNY
- LSB
- Sector
- MNY
- LSB
- Exchange
- MNY Nasdaq
- LSB NYSE
- Market Cap
- MNY 43.4M
- LSB 41.2M
- IPO Year
- MNY N/A
- LSB N/A
- Fundamental
- Price
- MNY $1.17
- LSB $2.71
- Analyst Decision
- MNY
- LSB
- Analyst Count
- MNY 0
- LSB 0
- Target Price
- MNY N/A
- LSB N/A
- AVG Volume (30 Days)
- MNY 93.7K
- LSB 82.0K
- Earning Date
- MNY 12-04-2024
- LSB 11-22-2024
- Dividend Yield
- MNY N/A
- LSB N/A
- EPS Growth
- MNY N/A
- LSB N/A
- EPS
- MNY N/A
- LSB N/A
- Revenue
- MNY $88,967,081.00
- LSB $79,415,311.00
- Revenue This Year
- MNY $26.64
- LSB $39.33
- Revenue Next Year
- MNY $25.46
- LSB $75.61
- P/E Ratio
- MNY N/A
- LSB N/A
- Revenue Growth
- MNY 28.08
- LSB N/A
- 52 Week Low
- MNY $0.76
- LSB $1.88
- 52 Week High
- MNY $4.70
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- MNY 49.89
- LSB 43.57
- Support Level
- MNY $1.12
- LSB $1.91
- Resistance Level
- MNY $1.29
- LSB $3.23
- Average True Range (ATR)
- MNY 0.09
- LSB 0.55
- MACD
- MNY -0.00
- LSB 0.16
- Stochastic Oscillator
- MNY 39.13
- LSB 53.57
About MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.